When you divest niche products to us, you're not handing them to a holding company. You're handing them to pharmacists who will own every aspect of that product's continued existence.
We handle the entire MA transfer process — regulatory, commercial, supply chain. Your team spends hours, not months.
Our integrated supply chain and own dispensing pharmacy mean patients never experience a gap. We guarantee continuity from day one.
Your divestment actively protects patient access. A measurable, reportable outcome for your sustainability commitments.
Too small for big specialty pharma. Too complex for a consultant. Too important for patients to lose.
Typical divestment timeline. Every transfer is different — this is the rhythm most of ours follow.
Product evaluation, regulatory status, supply chain, commercial viability. NDA signed upfront.
Full regulatory gap analysis, CMC review, pharmacovigilance assessment, supply chain mapping.
Commercial terms, transfer agreement, regulatory strategy for MA transfer per jurisdiction.
Simultaneous regulatory submissions, supply chain novation, safety stock build, QPPV handover.
Octopus Health is the registered MAH. Full chain operational. Your team is released.
You hold or are developing a marketing authorisation for a niche product but lack the infrastructure to commercialise it across EU markets. We bring GDP-licensed distribution, a dispensing pharmacy, regulatory management, and established wholesale relationships.
We use the Netherlands as Reference Member State for MRP/DCP procedures. Your product gains access to multiple EU markets through a single regulatory and commercial partner.
You retain the MA or we co-hold it — the commercial model is flexible. What matters is that the product reaches patients through a partner who controls every operational step.
Regulatory and safety decisions are made by registered pharmacists — not outsourced to project managers. Your product is in the hands of people who understand the pharmacology.
We operate a GDP-licensed pharmaceutical distribution hub from Soesterberg, the Netherlands. If you're a manufacturer, API supplier, or logistics provider looking for a reliable partner in EU pharma distribution — let's talk.
We work with EU-GMP certified manufacturers and are always evaluating new manufacturing partners for our growing portfolio.
Our GDP licence enables storage, handling, and distribution of medicinal products across the EU from our Dutch facility.
We maintain relationships with qualified API suppliers and actively seek reliable sources for niche active ingredients.
If you're a hospital pharmacy, community pharmacy, wholesaler, or healthcare institution struggling with access to niche medicines — we exist specifically for this. Our vertically integrated model and own dispensing pharmacy mean we can supply what others can't or won't.
Niche hospital medicines that are commercially unviable for major distributors but clinically essential for your patients. We supply directly and participate in hospital tenders.
We partner with national wholesalers across EU markets to ensure our portfolio reaches the pharmacies and hospitals that need it.
Niche medicines require a different commercial approach. We work with insurers and payers to ensure our products are accessible within reimbursement frameworks, while maintaining long-term commercial sustainability.
Whether you’re divesting, licensing, distributing, or sourcing — the conversation starts the same way.
